Miravant's SnET2 Fails Phase III; Stock Price Drops 75 Percent
By Aaron Lorenzo
Tuesday, January 15, 2002
Miravant Medical Technologies Inc. suffered a 75.6 percent stock drop Monday on negative Phase III data of an investigational drug to treat vision loss.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.